EL gained roughly 1.2% on the week to close at $87.58 — a quiet grind higher that masks a more complicated story underneath, where analyst initiations are landing well below the current price and earnings momentum scores are running close to decade highs.
The most telling signal this week came from the Street. Bernstein initiated coverage on June 11 with a Market Perform rating and a $82 target — 6% below where the stock already trades. That's a cautious opening statement from a firm entering the name for the first time. The broader analyst picture is split: Citigroup lifted its target to $110 in late May while maintaining Buy, and JP Morgan is at $99 with an Overweight rating. But the consensus sits at Hold, with 14 analysts parked there and a mean target of $95.12. That implies modest upside from current levels. Barclays holds at Equal-Weight with a $75 target, the most skeptical on the Street — a number now meaningfully below the trading price. The direction of travel after Q3 results in May was mostly target upgrades on maintained ratings, rather than genuine sentiment improvement. Bulls point to the Profit Recovery and Growth Plan, Mainland China strength, and the potential Puig merger angle. Bears flag currency volatility, soft travel retail, and continued pressure on operating margins in the EMEA region.
Positioning in the lending market is essentially a non-story. Availability is extraordinarily loose at 3,535% — meaning there are roughly 35 shares available to borrow for every one currently shorted. That ratio has tightened sharply this week from around 4,400%, but the absolute level remains far beyond what would create any friction for new short sellers. Borrowing costs are negligible at 0.46%, up modestly on the month but still among the cheapest in the sector. Short interest is just 3.1% of the free float, broadly flat over the past month after drifting down from early-May levels near 8 million shares. The ORTEX short score of 32.7 reflects this: no meaningful bearish conviction in the lending market, and no squeeze pressure building.
Options traders are slightly more relaxed than usual. The put/call ratio has drifted lower to 0.96 over the past two weeks, now running about 1.2 standard deviations below its 20-day average of 0.98. That shift away from defensive positioning aligns with the stock's 9% monthly gain. The 52-week PCR range stretches from 0.76 to 1.50, so the current reading sits in the lower third of that band — modestly constructive. It's not an aggressive call-buying surge, but the hedging demand that likely built ahead of May earnings has visibly unwound.
The earnings history is worth noting. May's Q3 print delivered a 6% single-day gain and extended to a 12% five-day move — a clean beat that drove most of the stock's recovery from its February lows. February's Q2 print went the other way sharply: a 17% single-day drop that briefly pushed the stock back toward multi-year lows. That binary pattern is important context as the next event approaches. The August 19 Q3 report is still nine weeks away, but the factor score backdrop has shifted considerably since February. EPS momentum ranks in the 84th percentile on a 30-day basis and the 89th percentile over 90 days — both significantly stronger than the setup heading into the February miss. Forward EPS estimates are growing year-on-year at a rate that ranks in the 93rd percentile across the universe.
The tension heading into the summer is whether the fundamental improvement already visible in earnings revision momentum can translate into a more decisive analyst re-rating — or whether the Bernstein initiation below the current price sets the tone for a cautious Street that continues to wait for cleaner evidence of the restructuring taking hold.
See the live data behind this article on ORTEX.
Open EL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
